Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

FENG Bing; GAO Ning; GAO Shengnan; ZHANG Yuxi; ZHANG Ranran; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2025.05.13

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

更新时间：2025-09-26

- Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 5, Pages: 579-583(2025)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.05.13
  CLC： R956
- Received：09 July 2024，
  
  Revised：2025-01-15，
  
  Accepted：26 January 2025，
  
  Published：15 March 2025
- 稿件说明：
移动端阅览
冯冰,高宁,高胜男,等.贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌的成本-效用分析[J].中国药房,2025,36(05):579-583.

FENG Bing,GAO Ning,GAO Shengnan,et al.Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(05):579-583.
冯冰,高宁,高胜男,等.贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌的成本-效用分析[J].中国药房,2025,36(05):579-583. DOI： 10.6039/j.issn.1001-0408.2025.05.13.

FENG Bing,GAO Ning,GAO Shengnan,et al.Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(05):579-583. DOI： 10.6039/j.issn.1001-0408.2025.05.13.

摘要

目的

从中国卫生体系角度出发，评估贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌（ES-SCLC）的经济性。

方法

根据ETER701研究数据构建分区生存模型，循环周期为3周，模拟ES-SCLC患者采用贝莫苏拜单抗联合安罗替尼和化疗方案或单纯化疗方案治疗10年的总成本、质量调整生命年（QALY）及增量成本-效果比（ICER），并采用单因素敏感性分析和概率敏感性分析验证模型的稳健性。意愿支付（WTP）阈值为3倍2023年我国人均国内生产总值（GDP），即268 074元/QALY。

结果

相比于单纯化疗方案，贝莫苏拜单抗联合安罗替尼和化疗方案可多获得0.438 QALY，成本则高出403 505.55元，ICER为922 031.37元/QALY，高于本研究设定的WTP阈值。单因素敏感性分析结果显示，贝莫苏拜单抗成本、无进展生存期状态的效用值及贴现率对基础分析结果的影响较大；概率敏感性分析结果证实该模型稳健，且贝莫苏拜单抗降价75.4%时，联合方案才具有经济性。

结论

从我国卫生体系角度出发，贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗ES-SCLC当前不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-utility of benmelstobart combined with anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer （ES-SCLC） from the perspective of China’s healthcare system.

METHODS

Based on the data from the ETER 701 study， a partitioned survival model was constructed with a cycle of 3 weeks to simulate the total cost， quality-adjusted life years （QALY）， and incremental cost-effectiveness ratio （ICER） over 10 years for patients with ES-SCLC treated with benmelstobart plus anlotinib and chemotherapy， or chemotherapy alone. One-way sensitivity analysis and probability sensitivity analysis were performed to verify the robustness of the simulation results. The willingness-to-pay （WTP） threshold was set at 3 times the per capita gross domestic product （GDP） of China in 2023， which amounted to 268 074 yuan/QALY.

RESULTS

Compared with chemotherapy alone， benmelstobart combined with anlotinib and chemotherapy gained 0.438 QALY more at the cost of 403 505.55 yuan more， with an ICER of 922 031.37 yuan/QALY， which was higher than the WTP threshold set in this study. One-way sensitivity analysis showed that benmelstobart’s cost and utility value of the progression-free survival state had a greater impact on the ICER value； probabilistic sensitivity analysis confirmed the robustness of the model； only when the price of benmelstobart was reduced by 75.4%， the combined regimen would be cost-effective.

CONCLUSIONS

The first-line treatment of ES-SCLC with benmelstobart combined with anlotinib and chemotherapy is not cost-effective from the perspective of China’s healthcare system at present.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

ZHENG R S ， ZHANG S W ， ZENG H M ， et al . Cancer incidence and mortality in China，2016 [J ] . J Natl Cancer Cent ， 2022 ， 2 （ 1 ）： 1 - 9 .

RUDIN C M ， BRAMBILLA E ， FAIVRE-FINN C ， et al . Small-cell lung cancer [J ] . Nat Rev Dis Primers ， 2021 ， 7 （ 1 ）： 3 .

JEFFREY P W ， PAZARES L . Emerging strategies for the treatment of small cell lung cancer：a review [J ] . JAMA Oncol ， 2023 ， 9 （ 3 ）： 419 - 429 .

FARAGO A F ， KEANE F K . Current standards for clinical management of small cell lung cancer [J ] . Transl Lung Cancer Res ， 2018 ， 7 （ 1 ）： 69 - 79 .

王立东 . 广泛期小细胞肺癌一线治疗现状及研究进展 [J ] . 中外医学研究， 2024 ， 22 （ 29 ）： 180 - 184 .

WANG L D . Current status and research progress of first-line treatment of extensive small cell lung cancer [J ] . Chin Foreign Med Res ， 2024 ， 22 （ 29 ）： 180 - 184 .

中华医学会肿瘤学分会，中华医学会杂志社 . 中华医学会肺癌临床诊疗指南： 2023版 [J ] . 中华肿瘤杂志， 2023 ， 45 （ 7 ）： 539 - 574 .

Oncology Society of Chinese Medical Association ， Chinese Medical Association Publishing House . Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer：2023 edition [J ] . Chin J Oncol ， 2023 ， 45 （ 7 ）： 539 - 574 .

BOUSSIOTIS V A . Molecular and biochemical aspects of the PD-1 checkpoint pathway [J ] . N Engl J Med ， 2016 ， 375 （ 18 ）： 1767 - 1778 .

CHENG Y ， YANG R ， CHEN J ， et al . 196MO anlotinib plus etoposide/carboplatin （EC） versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer （ES-SCLC）：a randomized，double-blind，parallel controlled，phase Ⅲ trial （ETER701） [J ] . ESMO Open ， 2024 ， 30 （ 10 ）： 2967 - 2976 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 3 - 5 .

LIU G E . China guidelines for pharmacoeconomic evaluations 2020 [M ] . Beijing ： China Market Publishing House ， 2020 ： 3 - 5 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

SHI F H ， SHANG Y ， RUI M J ， et al . Application of survHE package of R for health economic evaluation [J ] . Chin Health Econ ， 2020 ， 39 （ 9 ）： 9 - 14 .

李越，孔树佳，赵嫔，等 . 阿得贝利单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析 [J ] . 中国现代应用药学， 2024 ， 41 （ 9 ）： 1267 - 1274 .

LI Y ， KONG S J ， ZHAO P ， et al . Cost-effectiveness analysis of adebrelimab combined with chemotherapy in first line treatment of extensive stage small-cell lung cancer [J ] . Chin J Mod Appl Pharm ， 2024 ， 41 （ 9 ）： 1267 - 1274 .

YOU M J ， CHEN R J ， WU Q F ， et al . Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer [J ] . Front Pharmacol ， 2022 ， 13 ： 1019826 .

ZHANG Q L ， WU P ， HE X C ， et al . Cost-effectiveness analysis of camrelizumab vs . placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China [J ] . Front Oncol ， 2021 ， 11 ： 790373 .

WEN F ， ZHENG H R ， ZHANG P F ， et al . Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresec-table hepatocellular carcinoma：a cost-effectiveness analysis in China and the United States [J ] . Liver Int ， 2021 ， 41 （ 5 ）： 1097 - 1104 .

NAFEES B ， LLOYD A J ， DEWILDE S ， et al . Health state utilities in non-small cell lung cancer：an international study [J ] . Asia Pac J Clin Oncol ， 2017 ， 13 （ 5 ）： e195 - e203 .

DING D ， HU H B ， LI S S ， et al . Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer [J ] . J Natl Compr Canc Netw ， 2021 ， 19 （ 10 ）： 1141 - 1147 .

LI L Y ， WANG H ， CHEN X ， et al . First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer：a cost-effectiveness analysis from China [J ] . Chin Med J（Engl）， 2019 ， 132 （ 23 ）： 2790 - 2794 .

韩振中，李娜，刘茂柏，等 . 度伐利尤单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析 [J ] . 中国新药与临床杂志， 2021 ， 40 （ 5 ）： 373 - 378 .

HAN Z Z ， LI N ， LIU M B ， et al . Cost-effectiveness analysis of durvalumab combined with chemotherapy in first-line treatment of extensive stage small-cell lung cancer [J ] . Chin J New Drugs Clin Remedies ， 2021 ， 40 （ 5 ）： 373 - 378 .

ZHU Y W ， LIU K ， QIN Q ， et al . Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer：a cost-effectiveness analysis [J ] . Front Immunol ， 2023 ， 13 ： 1044678 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer

Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

Related Author

QI Ran

NIE Xuyang

LIU Xuting

GAO Shengnan

LIU Guoqiang

CHEN Qiuping

SHAO Mingyi

ZHANG Rongrong

Related Institution

Dept. of Clinical Pharmacology Research， the Fourth Hospital of Hebei Medical University

Dept. of Clinical Pharmacy， the Third Hospital of Hebei Medical University

Dept. of Gastroenterology， the First Affiliated Hospital of Henan University of Chinese Medicine

First College of Clinical Medicine， Henan University of Chinese Medicine

Hebei Society for Integrated Drug and Health Technology Assessment

⁰